Non metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy. Failures are much more frequent when tumours are locally advanced. For this reason, new strategies have been designed, among them combined radiotherapy and hormonotherapy, in most cases with a LHRH analog, neoadjuvant and/or concomitant and/or adjuvant. Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormono therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.